New Controlling Shareholder Takes 96.62% Voting Power, Appoints New CEO/Chairman, and Cancels Debt
GCAN has more than doubled off its 52-week low of $0.036 on light trading volume (0.1× avg).
Summary
Greater Cannabis Company has undergone a change of control, with Trafalgar Asset Management acquiring 96.62% of voting power, appointing a new CEO/Chairman, and canceling company debt, signaling a major restructuring effort.
Key Events · Corporate Governance and Compliance · GCAN
-
Change of Control
Trafalgar Asset Management, LLC, controlled by Porfirio Sanchez Talavera, acquired 7,628,665 shares of Series A Preferred Stock and 1,000 shares of Series B Preferred Stock, gaining 96.62% of the company's aggregate voting power.
-
New Leadership Appointed
Porfirio Sanchez Talavera was appointed Chief Executive Officer, Chairman of the Board, and a member of the Board of Directors. Former CEO Aitan Zacharin resigned from all officer positions and will resign as a director after the mandatory 10-day period.
-
Debt Cancellation
Contemporaneously with the share purchase, certain company indebtedness was compromised, settled, canceled, and extinguished, providing significant financial relief.
-
Strategic Shift for Distressed Company
This change of control and debt relief is a critical development for a company that recently reported severe financial distress and going concern doubts, indicating a potential turnaround strategy under new management.
Analysis · GCAN · Life Sciences
This SC 14F1 filing confirms a fundamental change in control for Greater Cannabis Company. Trafalgar Asset Management, LLC, now holds 96.62% of the voting power, effectively taking over the company. This event is critical, especially given the company's previously disclosed severe financial distress and going concern doubts. The simultaneous cancellation of company debt provides a much-needed lifeline, and the appointment of Porfirio Sanchez Talavera, with his background in restructuring and special situations, suggests a strategic effort to stabilize and potentially turn around the company. This represents a significant shift in the company's operational and financial trajectory.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GCAN was trading at $0.19 on OTC in the Life Sciences sector, with a market capitalization of approximately $183.4K. The 52-week trading range was $0.04 to $3.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.